6-KThe Wire
TAKEDA PHARMACEUTICAL CO LTD files 6-K
Filed Jun 5, 2026 · 28d ago · Accession 0001395064-26-000168
Plain English
Takeda Pharmaceutical Company Limited revised its FY2025 consolidated financial statements due to a jury verdict in the AMITIZA® antitrust litigation, which will be appealed. This revision impacts reported FY2025 earnings but does not change Core financial results for FY2025 or the FY2026 financial forecast.
Filing details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Ticker
- TAK
- CIK
- 1395064
- Form type
- 6-K
- Filing date
- Jun 5, 2026
- Report date
- Jun 5, 2026
- Document
- form6k_2x060526.htm
- Size
- 19 KB